Blueprint Medicines to Report Third Quarter 2021 Financial Results on Thursday, October 28, 2021
Blueprint Medicines Corporation (NASDAQ: BPMC) will host a live conference call on October 28, 2021, at 8:30 a.m. ET to discuss its third quarter 2021 financial results and provide a corporate update. Interested participants can dial 844-200-6205 (domestic) or 929-526-1599 (international) using conference ID 963004. A webcast will be accessible on their website and archived for 30 days. Blueprint Medicines focuses on developing precision therapies for cancer and hematologic disorders, with a strong research platform for targeted treatment.
- None.
- None.
CAMBRIDGE, Mass., Oct. 21, 2021 /PRNewswire/ -- Blueprint Medicines Corporation (NASDAQ: BPMC), today announced that it will host a live conference call and webcast at 8:30 a.m. ET on Thursday, October 28, 2021 to report its third quarter 2021 financial results and provide a corporate update.
To access the live conference call, please dial 844-200-6205 (domestic) or 929-526-1599 (international), and refer to conference ID 963004. A webcast of the call will also be available under "Events and Presentations" in the Investors & Media section of the Blueprint Medicines website at http://ir.blueprintmedicines.com/. The archived webcast will be available on Blueprint Medicines' website approximately two hours after the conference call and will be available for 30 days following the call.
About Blueprint Medicines
Blueprint Medicines is a global precision therapy company that invents life-changing therapies for people with cancer and hematologic disorders. Applying an approach that is both precise and agile, we create medicines that selectively target genetic drivers, with the goal of staying one step ahead across stages of disease. Since 2011, we have leveraged our research platform, including expertise in molecular targeting and world-class drug design capabilities, to rapidly and reproducibly translate science into a broad pipeline of precision therapies. Today, we are delivering approved medicines directly to patients in the United States and Europe, and we are globally advancing multiple programs for genomically defined cancers, systemic mastocytosis, and cancer immunotherapy. For more information, visit www.BlueprintMedicines.com and follow us on Twitter (@BlueprintMeds) and LinkedIn.
View original content to download multimedia:https://www.prnewswire.com/news-releases/blueprint-medicines-to-report-third-quarter-2021-financial-results-on-thursday-october-28-2021-301405451.html
SOURCE Blueprint Medicines Corporation
FAQ
When will Blueprint Medicines report its third quarter 2021 financial results?
How can I access the conference call hosted by Blueprint Medicines?
Is there a webcast available for Blueprint Medicines' financial results call?
What is the focus of Blueprint Medicines?
